Is CJC-1295 with GHRP-6 legal in the United Kingdom?

The same two-receptor pairing as the GHRP-2 version with the hungriest secretagogue of the group in the second slot. GHRP-6 has published human pharmacokinetics in nine male volunteers, with an elimination half-life of about 2.5 hours, against a GHRH half that either lasts days or minutes depending on which molecule is actually in the vial. Nobody has studied the blend.

GHRP-6 is the original growth hormone releasing hexapeptide and the one with the strongest appetite effect in the family. That is why it persists in this market: people who want to eat choose it deliberately, and people who do not want to eat find out about it the hard way.

Mechanism: GHRP-6 is a hexapeptide agonist at the growth hormone secretagogue receptor, the ghrelin receptor, which triggers a growth hormone pulse and also drives appetite, and at higher exposures raises cortisol and prolactin more than the newer selective agents. The GHRH analogue raises pulse amplitude at a separate receptor.

Regulatory history: Not approved. GHRP-6 has been studied in Cuba for tissue protection indications but holds no marketing authorisation in the United States, and the combination has never been evaluated anywhere.

Licenses medicines for the UK market. A compound without a marketing authorisation is an unlicensed medicine, which can only lawfully be supplied for human use through a prescriber under the specials scheme, not sold as a research product.

The classification above is the The Longevity Archive reading of Medicines and Healthcare products Regulatory Agency listings for CJC-1295 with GHRP-6 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.